Table 3.
Trends of antimicrobial susceptibilities of gram negative isolates (excluding Salmonella) among pediatric and adult patients (n = 96).
| AMP | COT | CIP | LEV | CFM | CAZ | GEN | AK | IPM | MRP | PIT | C | PB | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Escherichia coli (n = 20) | Pediatric (n = 8) |
4 (50.0) | 2 (25.0) | 0 (0.0) | 0 (0.0) | 2 (25.0) | 2 (25.0) | 4 (50.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (25.0) | 0 (0.0) | — |
| Adults (n = 12) |
8 (66.7) | 4 (33.3) | 10 (83.3) | 10 (83.3) | 8 (66.7) | 8 (66.7) | 4 (33.3) | 4 (33.3) | 2 (16.7) | 2 (16.7) | 2 (16.7) | 4 (33.3) | — | |
|
| ||||||||||||||
| Klebsiella spp. (n = 7) | Pediatric (n = 3) |
3 (100) | 2 (66.7) | 2 (66.7) | 1 (33.3) | 1 (33.3) | 0 (0.0) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (33.3) | 0 (0.0) | — |
| Adults (n = 4) |
4 (100) | 3 (75) | 3 (75.0) | 3 (75.0) | 3 (75.0 | 3 (75.0 | 3 (75.0 | 3 (75.0) | 2 (50.0) | 2 (50.0) | 2 (50.0) | 2 (50.0) | — | |
|
| ||||||||||||||
| Pseudomonas spp. (n = 39) | Pediatric (n = 8) |
— | — | 2 (25.0) | 1 (12.5) | — | 1 (12.5) | 2 (25.0) | 1 (12.5) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 0 (0.0) | 0 (0.0) |
| Adults (n = 31) |
— | — | 30 (96.7) | 27 (87.0) | — | 6 (19.3) | 21 (67.7) | 18 (58.0) | 7 (22.5) | 7 (22.5) | 9 (29.0) | 4 (12.9) | 0 (0.0) | |
|
| ||||||||||||||
| Acinetobacter spp. (n = 30) | Pediatric (n = 9) |
— | 5 (55.5) | 4 (44.4) | 2 (22.2) | 4 (44.4) | 4 (44.4) | 5 (55.5) | 3 (33.3) | 1 (11.1) | 1 (11.1) | 1 (11.1) | 3 (33.3) | — |
| Adults (n = 21) |
— | 11 (52.3) | 10 (47.2) | 8 (38.1) | 14 (66.7) | 14 (66.7) | 8 (38.1) | 8 (38.1) | 5 (23.8) | 5 (23.8) | 5 (23.8) | 8 (38.1) | — | |
AMP = ampicillin, COT = cotrimoxazole (trimethoprim + sulfamethoxazole), CIP = ciprofloxacin, LEV = levofloxacin, CFM = cefixime, CAZ = ceftazidime, GEN = gentamycin, AK = amikacin, IPM = imipenem, MRP = meropenem, PIT = piperacillin + tazobactam, C = chloramphenicol, PB = polymyxin.